Statin users without an APOE-ε4 allele have increased insulin resistance

Journal of Alzheimer's Disease

Volumn 19, Issue 4, 2010, Pages 1149-1153

  Vanfossen, Brian T ^a,b   Watson, G Stennis ^a,b   Baker, Laura D ^a,b   Rhoads, Kristoffer W ^a,b   Cholerton, Brenna A ^a,b   Reger, Mark A ^a,b   Plymate, Stephen R ^a,c   Schellenberg, Gerald ^a,b   Craft, Suzanne ^a,b  

^a VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Alzheimer's disease; Dementia; Diabetes; Insulin; Statin

Indexed keywords

APOLIPOPROTEIN E; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

AGED; ALLELE; ALZHEIMER DISEASE; ARTICLE; CONTROLLED STUDY; DEMENTIA; FEMALE; GENOTYPE; HOMEOSTASIS; HUMAN; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

EID: 77950361951     PISSN: 13872877     EISSN: None     Source Type: Journal    
DOI: 10.3233/JAD-2010-1319     Document Type: Article

References (27)

1. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, Roses AD, Haines JL, Pericak-Vance MA (1993) Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 261, 921-923.
2. Craft S,Watson GS (2004) Insulin and neurodegenerative disease: shared and specific mechanisms. Lancet Neurol 3, 169-178.
3. Peila R, Rodriguez BL, Launer LJ (2002) Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies: The Honolulu-Asia Aging Study. Diabetes 51, 1256-1262.
4. Leibson CL, Rocca WA, Hanson VA, Cha R, Kokmen E, O'Brien PC, Palumbo PJ (1997) The risk of dementia among persons with diabetes mellitus: a population-based cohort study. Ann N Y Acad Sci 826, 422-427.
5. Craft S, Asthana S, Schellenberg G, Cherrier M, Baker LD, Newcomer J, Plymate S, Latendresse S, Petrova A, Raskind M, Peskind E, Lofgreen C, Grimwood K (1999) Insulin metabolism in Alzheimer's disease differs according to apolipoprotein E genotype and gender. Neuroendocrinology 70, 146-152.
6. Razay G, Wilcock GK (1994) Hyperinsulinaemia and Alzheimer's disease. Age Ageing 23, 396-399.
7. Meneilly GS, Cheung E, Tessier D, Yakura C, Tuokko H (1993) The effect of improved glycemic control on cognitive functions in the elderly patient with diabetes. J Gerontol 48, M117-121.
8. Craft S, Peskind E, Schwartz MW, Schellenberg GD, Raskind M, Porte D, Jr. (1998) Cerebrospinal fluid and plasma insulin levels in Alzheimer's disease: relationship to severity of dementia and apolipoprotein E genotype. Neurology 50, 164-168.
9. Craft S, Asthana S, Cook DG, Baker LD, CherrierM, Purganan K, Wait C, Petrova A, Latendresse S, Watson GS, Newcomer JW, Schellenberg GD, Krohn AJ (2003) Insulin dose-response effects on memory and plasma amyloid precursor protein in Alzheimer's disease: interactions with apolipoprotein E genotype. Psychoneuroendocrinology 28, 809-822.
10. Kamagate A, Qu S, Perdomo G, Su D, Kim DH, Slusher S, Meseck M, Dong HH (2008) FoxO1 mediates insulindependent regulation of hepatic VLDL production in mice. J Clin Invest 118, 2347-2364.
11. Refolo LM, Malester B, LaFrancois J, Bryant-Thomas T, Wang R, Tint GS, Sambamurti K, Duff K, PappollaMA(2000) Hypercholesterolemia accelerates the Alzheimer's amyloid pathology in a transgenic mouse model. Neurobiol Dis 7, 321-331.
12. Morris MC, Evans DA, Bienias JL, Tangney CC, Bennett DA, Aggarwal N, Schneider J, Wilson RS (2003) Dietary fats and the risk of incident Alzheimer disease. Arch Neurol 60, 194-200.
13. Kivipelto M, Helkala EL, LaaksoMP, HanninenT,Hallikainen M, Alhainen K, Soininen H, Tuomilehto J, Nissinen A (2001) Midlife vascular risk factors and Alzheimer's disease in later life: longitudinal, population based study. BMJ 322, 1447-1451.
14. Reilly SL, Ferrell RE,KottkeBA, Kamboh MI, SingCF (1991) The gender-specific apolipoprotein E genotype influence on the distribution of lipids and apolipoproteins in the population of Rochester, MN. I. Pleiotropic effects on means and variances. Am J Hum Genet 49, 1155-1166.
15. Riekse RG, Li G, Petrie EC, Leverenz JB, Vavrek D, Vuletic S, Albers JJ, Montine TJ, Lee VM, Lee M, Seubert P, Galasko D, Schellenberg GD, Hazzard WR, Peskind ER (2006) Effect of statins on Alzheimer's disease biomarkers in cerebrospinal fluid. J Alzheimers Dis 10, 399-406.
16. Silbert LC (2007) Does statin use decrease the amount of Alzheimer disease pathology in the brain? Neurology 69, E8- 11.
17. Auer J, Berent R,Weber T, Eber B (2002) Clinical significance of pleiotropic effects of statins: lipid reduction and beyond. Curr Med Chem 9, 1831-1850.
18. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34, 939-944.
19. Petersen RC (2004) Mild cognitive impairment as a diagnostic entity. J Intern Med 256, 183-194.
20. Kahn SE, Leonetti DL, Prigeon RL, Boyko EJ, Bergstrom RW, Fujimoto WY (1995) Relationship of proinsulin and insulin with noninsulin-dependent diabetes mellitus and coronary heart disease in Japanese-American men: impact of obesity- clinical research center study. J Clin Endocrinol Metab 80, 1399-1406.
21. Lansang MC, Williams GH, Carroll JS (2001) Correlation between the glucose clamp technique and the homeostasis model assessment in hypertension. Am J Hypertens 14, 51-53.
22. Mattis S (1988) Dementia Rating Scale, Psychological Assessment Resources, Odessa, FL.
23. Sparks DL, Connor DJ, Sabbagh MN, Petersen RB, Lopez J, Browne P (2006) Circulating cholesterol levels, apolipoprotein E genotype and dementia severity influence the benefit of atorvastatin treatment in Alzheimer's disease: results of the Alzheimer's Disease Cholesterol-Lowering Treatment (ADCLT) trial. Acta Neurol Scand Suppl 185, 3-7.
24. Rea TD, Breitner JC, Psaty BM, Fitzpatrick AL, Lopez OL, Newman AB, Hazzard WR, Zandi PP, Burke GL, Lyketsos CG, Bernick C, Kuller LH (2005) Statin use and the risk of incident dementia: the Cardiovascular Health Study. Arch Neurol 62, 1047-1051.
25. Arvanitakis Z, Schneider JA, Wilson RS, Bienias JL, Kelly JF, Evans DA, Bennett DA (2008) Statins, incident Alzheimer disease, change in cognitive function, and neuropathology. Neurology 70, 1795-1802.
26. Wolozin B, Kellman W, Ruosseau P, Celesia GG, Siegel G (2000) Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch Neurol 57, 1439-1443.
27. Haag MD, Hofman A, Koudstaal PJ, Stricker BH, Breteler MM (2009) Statins are associated with a reduced risk of Alzheimer disease regardless of lipophilicity. The Rotterdam Study. J Neurol Neurosurg Psychiatry 80, 13-17.